The first synthesis of topopyrone C, a natural compound and inhibitor of Topoisomerase 1, has been carried out by Mars-chalk alkylation of 1-hydroxy-3,6,8-trimethoxyanthraquinone, followed by a Baker-Venkataraman chain elongation and an acidcatalyzed cyclization for the construction of the pyrone ring. (c) 2006 Elsevier Ltd. All rights reserved.
Utilization of Sulfide, Sulfoxide, and Sulfone Groups as Regiochemical Control Elements in the Diels–Alder Reaction of Naphthoquinones
作者:Masatomo Iwao、Tsukasa Kuraishi
DOI:10.1246/bcsj.60.4051
日期:1987.11
The Diels–Alderreactions of 2-phenylthio-, 2-phenylsulfinyl-, and 2-phenylsulfonyl-1,4-naphthoquinones, which were unsymmetrically substituted by methoxyl group on the benzenoid ring, with some vinylketene acetals were studied. The regioselectivity of the reactions was cleanly controlled by each of these sulfur substituents. In addition, the reactivity of the naphthoquinones were greatly enhanced
Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors
作者:Sabrina Dallavalle、Sonia Gattinoni、Stefania Mazzini、Leonardo Scaglioni、Lucio Merlini、Stella Tinelli、Giovanni L. Beretta、Franco Zunino
DOI:10.1016/j.bmcl.2007.12.055
日期:2008.2
A series of structurally simple analogues of natural topopyrone C were synthesized and tested for cytotoxic and topoisomerase I inhibitory activities. The removal of the hydroxyl groups at the 5 and 9 positions resulted in an increased cytotoxic potency and ability to stabilize topoisomerase-mediated cleavage. In addition, the results suggest that some structural features, such as the pyrone ring and
METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
申请人:Haggerty Timothy J.
公开号:US20140335050A1
公开(公告)日:2014-11-13
The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.